Puma Biotechnology (PBYI) Equity Average (2017 - 2025)
Historic Equity Average for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $110.0 million.
- Puma Biotechnology's Equity Average rose 8393.94% to $110.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.0 million, marking a year-over-year increase of 8393.94%. This contributed to the annual value of $72.8 million for FY2024, which is 9396.0% up from last year.
- Per Puma Biotechnology's latest filing, its Equity Average stood at $110.0 million for Q3 2025, which was up 8393.94% from $100.9 million recorded in Q2 2025.
- Puma Biotechnology's Equity Average's 5-year high stood at $110.0 million during Q3 2025, with a 5-year trough of -$6.7 million in Q4 2021.
- In the last 5 years, Puma Biotechnology's Equity Average had a median value of $28.1 million in 2023 and averaged $40.6 million.
- In the last 5 years, Puma Biotechnology's Equity Average tumbled by 10874.45% in 2021 and then surged by 90989.57% in 2023.
- Over the past 5 years, Puma Biotechnology's Equity Average (Quarter) stood at -$6.7 million in 2021, then soared by 427.37% to $21.9 million in 2022, then skyrocketed by 110.64% to $46.1 million in 2023, then soared by 77.05% to $81.6 million in 2024, then skyrocketed by 34.78% to $110.0 million in 2025.
- Its Equity Average was $110.0 million in Q3 2025, compared to $100.9 million in Q2 2025 and $94.6 million in Q1 2025.